Clinical Trials Browser

Adenocarcinoma × Breast × 1 year × Clear all

NCT00417495 2026-03-16

IGASSU

Phase 2 Completed

Adenocarcinoma, Breast Neoplasms

NCT00904410 2026-03-13

CHIMTEP

Phase 4 Completed

Adenocarcinoma, Breast Neoplasms

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Phase 1/2 Recruiting

BreastGynecologicThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07218003 2025-10-24

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Phase 1 Recruiting

BreastGastrointestinalGenitourinaryGynecologicThoracic

Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT07117214 2025-08-12

A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers

Phase 1 Not yet recruiting

Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung